Relapse Prevention Simulator — підтримувальна ЕСТ для профілактики рецидиву. Illustrative model of continuation strategy, treatment-interval tapering, and relapse-risk monitoring after a successful acute ECT course.
Electroconvulsive therapy remains one of the most effective treatments in psychiatry for severe, treatment-resistant, or life-threatening depressive episodes, with acute response rates of 50–70% and remission rates near 50% even in patients who failed multiple medication trials. But remission achieved through an acute course of ECT is fragile if left unprotected: without any continuation treatment, most patients relapse within months. Recognizing this threshold — and planning for it before the acute course even ends — is the foundation of durable recovery.
Achieving remission with an acute ECT course resets a severe depressive episode, but it does not change the underlying vulnerability that produced the episode in the first place. Historical data — before continuation strategies were standardized — showed relapse rates as high as 50–95% within six months when patients received no continuation treatment at all (Sackeim et al., JAMA 2001). This is comparable to, or worse than, stopping any effective acute treatment abruptly: the biological and psychosocial factors that triggered the episode remain, and the newly achieved remission is biologically unstable without reinforcement.
The acute course itself is typically 6–12 sessions delivered two to three times weekly over several weeks. Response is usually tracked with a standardized symptom rating scale, and a course is considered complete once the patient reaches remission (very low symptom scores) or a robust response with a plateau in further improvement. The moment that plateau is reached, the clinical team should already have a continuation plan ready — not one improvised afterward.
Not all patients face equal relapse risk after acute ECT. Established risk factors used to individualize the continuation plan include:
• Medication-resistant index episode (failure of ≥2 adequate antidepressant trials before ECT) • Psychotic features during the index episode • Recurrent illness course — three or more prior major depressive episodes • Residual subsyndromal symptoms at the end of the acute course (incomplete remission) • Comorbid anxiety, personality pathology, or chronic psychosocial stressors • Older age and medical comorbidity, which independently predict relapse in some cohorts
Patients with several of these features are those for whom the evidence most strongly favors an assertive continuation strategy — typically combined pharmacotherapy plus maintenance ECT — rather than pharmacotherapy alone.
The single most consistent predictor of relapse after ECT remission is the absence of any continuation treatment. Whatever the chosen strategy, having one in place — planned before the last acute session — is the single highest-leverage decision in the entire care pathway.
Three well-studied continuation strategies exist after acute ECT remission. The choice is individualized based on relapse risk factors, prior medication response, treatment burden, access, and patient preference. The landmark CORE (Consortium for Research in ECT) trials directly compared these options and remain the backbone of current continuation-treatment guidelines.
The simplest and most accessible option: an antidepressant regimen (often the medication class the patient responded best to historically, or a new evidence-based combination) is continued or initiated at the end of the ECT course. The CORE study demonstrated that combination nortriptyline plus lithium reduced 6-month relapse to approximately 39%, compared with 84% on placebo — a dramatic benefit, but still leaving a substantial minority of patients relapsing.
Pharmacotherapy alone is generally favored for patients with lower relapse-risk profiles, good prior medication tolerability, easy access to outpatient psychiatric follow-up, and a preference to avoid repeated ECT sessions. It requires close monitoring of medication adherence and side effects, and often benefits from concurrent psychotherapy.
Maintenance ECT extends the same treatment modality that achieved remission, delivered on a tapering, then fixed, outpatient schedule (see Stage 3). The CORE continuation trial found that M-ECT alone produced relapse rates comparable to combination pharmacotherapy, making it a reasonable option particularly for patients who are medication-intolerant, medication-resistant, or who responded dramatically and rapidly to the acute ECT course itself.
M-ECT requires greater logistic commitment — recurring visits to an ECT suite, anesthesia each session, and a caregiver or transportation plan — but avoids daily medication burden and offers a treatment modality with a track record of efficacy in the individual patient already established during the acute course.
For patients at the highest documented relapse risk — recurrent, severe, psychotic, or treatment-resistant illness — current evidence and expert guidelines generally favor combining continuation pharmacotherapy with maintenance ECT rather than relying on either alone. The rationale is complementary mechanisms: pharmacotherapy provides continuous background protection between ECT sessions, while M-ECT delivers a periodic, robust anti-depressant effect that resets symptom trajectory if early drift occurs.
In practice, combined strategies allow more flexible tapering: as stability accumulates, the ECT interval can lengthen while medication continues, or medication can eventually be simplified while M-ECT continues at a stable interval — individualized to the patient's trajectory.
No single continuation strategy is universally superior — the CORE trials found combination pharmacotherapy and maintenance ECT alone to be roughly comparable for average-risk patients, while combining both modalities is generally reserved for and most beneficial in the highest-risk subgroup.
When maintenance ECT is part of the continuation plan, the treatment interval is not fixed — it is deliberately tapered. Sessions start close together, mirroring the tail end of the acute course, and are gradually spaced further apart as the clinical team confirms the patient remains stable at each new, longer interval. This taper is one of the most carefully individualized elements of the entire ECT care pathway.
While every program individualizes the exact cadence, a commonly used illustrative taper looks like this:
• Weeks 0–4: weekly sessions — reinforcing the remission achieved during the acute course, when relapse risk is at its peak • Weeks 4–12: sessions every 2 weeks — the interval lengthens once early stability is confirmed • Weeks 12–24: sessions every 3 weeks — continued lengthening contingent on maintained remission • Beyond week 24: monthly sessions — the typical long-term maintenance rhythm for patients who remain stable
Each step of the taper is contingent, not automatic: if symptom rating scores drift upward at any point (see Stage 4), the interval is tightened back to the previous, more frequent step rather than continuing to lengthen on schedule.
Stopping ECT abruptly after the acute course — or lengthening the interval too quickly — removes the periodic reinforcement that keeps the depressive episode in remission while other continuation elements (pharmacotherapy, psychotherapy, psychosocial stabilization) take full effect. A gradual taper allows:
• Early detection of any destabilization while treatment is still close together, and easy to intensify again • A "step-down" structure that mirrors how many other maintenance medical treatments are gradually withdrawn (rather than trial withdrawal decisions being made from a fixed, arbitrary interval) • Patient and caregiver confidence-building — each successfully tolerated longer interval is itself evidence of durable improvement
The taper is best understood as an adaptive control system: the interval only lengthens when there is positive evidence of continued stability at the current interval, not simply because time has passed.
The taper is individualized, not templated: some patients taper to monthly M-ECT within 3 months; others remain on a biweekly schedule for a year or more before further lengthening is attempted. The schedule always yields to clinical evidence of stability or early warning signs, never the reverse.
Whichever continuation strategy is chosen, ongoing, structured symptom monitoring is what allows the care team to detect relapse risk before a full depressive relapse occurs — and to intervene early, by tightening the treatment interval, adjusting medication, or adding a treatment modality, rather than waiting until the patient has fully relapsed.
A structured rating scale — the Montgomery-Åsberg Depression Rating Scale (MADRS), the Patient Health Questionnaire-9 (PHQ-9), or the Hamilton Depression Rating Scale (HDRS) — is administered at every continuation visit, whether that is an M-ECT session, a medication management appointment, or a psychotherapy check-in. This creates a longitudinal trend line rather than a single snapshot, and trend direction matters more than any single score.
A score that remains flat and low, near the remission threshold established at the end of the acute course, indicates continued stability. A score that begins drifting upward over two or more consecutive assessments — even if each individual score remains below full relapse criteria — is treated as an early warning sign requiring a proactive response, not passive observation.
When monitoring detects early drift, several responses are available, individualized to the patient's situation and the magnitude of the change:
• Tighten the M-ECT interval back to the previous, more frequent step in the taper • Add or intensify pharmacotherapy, or adjust dosing of an existing regimen • Increase the frequency of clinical contact and psychosocial support • Add or intensify psychotherapy addressing the specific stressor or symptom cluster driving the change • In pharmacotherapy-only patients showing significant drift, consider reintroducing M-ECT sessions
The explicit goal of this monitoring loop is to intervene while the patient is in an early-warning state rather than after a full depressive relapse has occurred — early-warning interventions are typically far less intensive than the acute course that would otherwise be required to treat a full relapse.
Relapse prevention is not a single decision made at the end of the acute course — it is a continuous feedback loop. The interval, the medication regimen, and the psychosocial supports are all adjustable levers, and rating-scale trends are the signal that tells the care team when to pull them.
There is no single endpoint that applies to every patient on maintenance ECT. Some patients — particularly those with recurrent, severe, or treatment-resistant illness across multiple prior episodes — do best with indefinite maintenance ECT sustained at a stable, well-tolerated interval, sometimes for years. Others demonstrate such durable stability that maintenance treatment can eventually be tapered off entirely, with pharmacotherapy or psychotherapy alone sufficient to sustain wellness.
For a subset of patients — those with a history of multiple severe episodes, episodes triggered with minimal or no precipitant, incomplete response to pharmacotherapy across trials, or prior relapse despite a reasonable continuation attempt — long-term, potentially indefinite maintenance ECT at a stable interval (often monthly, sometimes longer) is a legitimate and often the most protective long-term plan. This mirrors how other chronic, relapsing medical conditions are managed with sustained maintenance therapy rather than time-limited courses.
For these patients, the treatment relationship becomes a stable, low-burden part of ongoing care: infrequent sessions, routine monitoring, and periodic reassessment of whether the interval itself can still be safely lengthened further.
Other patients — often those with a single or few prior episodes, strong response to pharmacotherapy independent of ECT, resolved or well-managed psychosocial stressors, and a long stretch of demonstrated stability at increasingly long M-ECT intervals — become candidates for tapering off maintenance ECT altogether. This is approached the same way the interval itself was lengthened: gradually, contingent on continued stability, with rating-scale monitoring continuing through and beyond the taper-off period, and an explicit plan for how quickly M-ECT would be resumed if warning signs reappear.
The decision to taper off is never made purely because a fixed amount of time has elapsed. It is made because the accumulated evidence — rating scale trends, tolerated interval length, psychosocial stability, and patient preference — supports it.
The long-term maintenance plan is revisited periodically — commonly every 6 to 12 months, or sooner if circumstances change — rather than fixed permanently at either extreme. A patient initially placed on indefinite maintenance may later demonstrate enough sustained stability to attempt a careful taper; a patient who successfully tapered off may need M-ECT reintroduced if life stressors or early warning signs recur. This flexibility, built on continuous monitoring rather than a rigid calendar, is what allows maintenance ECT to be individualized across an entire lifespan of care rather than a single static prescription.
The long-term goal of maintenance ECT is not simply the absence of relapse — it is sustained functional wellness, individualized to each patient's own risk profile and response, revisited as often as needed, and never treated as a decision made once and left unexamined.